Evolus, Inc. Common Stock

EOLS

$7.97

Name : Evolus, Inc. Common Stock

Sector : Healthcare

Industry: Drug Manufacturers - Specialty & Generic

Mark. Cap: $526,421,984.00

EPSttm : -0.53

Evolus, Inc. Common Stock

$7.97

1.40%

$0.11

EOLS — Price & Float Short

—— Fair value ★ EPS beat ★ EPS miss —— Target Price

Float Short %

9.56

Margin Of Safety %

Put/Call OI Ratio

0.02

EPS Next Q Diff

0.13

EPS Last/This Y

0.75

EPS This/Next Y

0.34

Price

7.98

Target Price

Analyst Recom

1.33

Performance Q

11.78

Upside

-332.7%

Beta

1.33

Ticker: EOLS

20 items of 1

Date	Symbol	Latest	P/C OI	P/C Vol	Total OI
2026-08-28	EOLS	8.89	0.04	0.00	9483
2026-08-31	EOLS	9.1	0.04	0.33	9213
2026-09-01	EOLS	9.08	0.042862002494614	0	9197
2026-09-02	EOLS	9.06	0.04	0.19	9107
2026-09-03	EOLS	9.06	0.04	0.00	9262
2026-09-04	EOLS	9.31	0.04	0.00	9683
2026-09-08	EOLS	8.89	0.04	0.13	9689
2026-09-09	EOLS	8.56	0.04	0.00	9687
2026-09-10	EOLS	7.93	0.04	0.16	11183
2026-09-11	EOLS	7.84	0.04	0.00	11178
2026-09-14	EOLS	7.91	0.04	0.00	11163
2026-09-15	EOLS	7.91	0.03	0.02	12112
2026-09-16	EOLS	8	0.03	0.00	11825
2026-09-17	EOLS	7.99	0.02	0.00	16853
2026-09-18	EOLS	7.82	0.02	0.01	17254
2026-09-21	EOLS	7.98	0.02	0.00	17330
2026-09-22	EOLS	8.25	0.02	0.00	17326
2026-09-23	EOLS	7.99	0.02	0.00	17326
2026-09-24	EOLS	7.86	0.02	0.00	17492
2026-09-25	EOLS	7.99	0.02	0.00	17495
Date	Symbol	Latest	P/C OI	P/C Vol	Total OI

20 items 1 of 1

20 items of 1

Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year
2026-08-28	EOLS	8.82	59.4	5.0	-0.04
2026-08-31	EOLS	9.10	59.4	2.6	-0.04
2026-09-01	EOLS	9.07	59.4	2.9	-0.04
2026-09-02	EOLS	9.06	59.4	30.8	-0.04
2026-09-03	EOLS	9.02	59.4	30.8	-0.04
2026-09-04	EOLS	9.30	59.4	31.2	-0.04
2026-09-08	EOLS	8.90	59.4	30.4	-0.04
2026-09-09	EOLS	8.53	59.4	30.4	-0.04
2026-09-10	EOLS	7.92	59.4	30.0	-0.04
2026-09-11	EOLS	7.83	59.4	30.8	-0.04
2026-09-14	EOLS	7.92	59.4	31.0	-0.04
2026-09-15	EOLS	7.91	59.4	30.9	-0.04
2026-09-16	EOLS	7.91	59.4	30.9	-0.04
2026-09-17	EOLS	7.99	59.4	30.9	-0.04
2026-09-18	EOLS	7.82	59.4	30.6	-0.05
2026-09-21	EOLS	7.97	59.4	31.0	-0.05
2026-09-22	EOLS	8.25	59.4	31.2	-0.05
2026-09-23	EOLS	7.99	59.4	30.5	-0.05
2026-09-24	EOLS	7.86	59.4	30.7	-0.05
2026-09-25	EOLS	7.98	59.4	31.0	-0.05
Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year

20 items 1 of 1

19 items of 1

Date	Ticker	Insider Transactions	Institutional Transactions	Float Short
2026-08-28	EOLS	-1.96	6.30	10.11
2026-08-31	EOLS	-1.96	6.32	10.11
2026-09-01	EOLS	-1.96	6.32	10.11
2026-09-02	EOLS	-1.96	6.32	10.11
2026-09-03	EOLS	-1.96	6.32	10.11
2026-09-04	EOLS	-1.96	6.32	10.11
2026-09-08	EOLS	-3.19	9.29	10.11
2026-09-09	EOLS	-3.19	9.29	10.11
2026-09-10	EOLS	-3.19	9.29	10.11
2026-09-11	EOLS	-3.17	9.29	9.28
2026-09-14	EOLS	-3.17	9.28	9.28
2026-09-15	EOLS	-3.17	9.28	9.28
2026-09-16	EOLS	-3.17	9.28	9.28
2026-09-17	EOLS	-3.17	9.28	9.28
2026-09-18	EOLS	-3.17	9.28	9.28
2026-09-21	EOLS	-1.26	9.30	9.28
2026-09-23	EOLS	-1.26	9.30	9.28
2026-09-24	EOLS	-1.26	9.30	9.28
2026-09-25	EOLS	-1.26	9.30	9.56
Date	Ticker	Insider Transactions	Institutional Transactions	Float Short

19 items 1 of 1

Last Quarter Act. EPS

-0.09

Avg. EPS Est. Current Quarter

-0.06

Avg. EPS Est. Next Quarter

0.04

Insider Transactions

-1.26

Institutional Transactions

9.3

Beta

1.33

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

55.2

Max Drawdown 5-Year %

-77.5

Target Price

P/E

Forward P/E

31.25

PEG

P/S

1.66

P/B

P/Free Cash Flow

EPS

-0.53

Average EPS Est. Cur. Y

-0.05

EPS Next Y. (Est.)

0.29

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

-10.85

Relative Volume

0.44

Return on Equity vs Sector %

84.8

Return on Equity vs Industry %

105

EPS 1 7Days Diff

EPS 1 30Days Diff

EBIT Estimation

◆ EOLS Healthcare

$7.97

📉

Swing / Pullback

Buy the dip on strong trends

N/A

WEAK

Trend

2/20

Pullback

22/25

Volume

11/15

Valuation

12/20

TP/AR

2/10

Options

8/10

RSI

47.3

Range 1M

16.6%

Sup Dist

2.5%

🚀

Momentum Growth

Ride accelerating trends

N/A

WEAK

Momentum

4/25

Growth

25/30

Estimates

1/20

Inst/Vol

8/15

Options

6/10

EPS Yr

89.2%

EPS NY

636.8%

52W%

73.7%

💎

Long-Term Value

Quality companies, undervalued

N/A

WEAK

🟢 BUY +44.8% upside

Quality

7/30

Valuation

11/30

Growth

17/25

Stability

7/10

LT Trend

0/5

Upside

+44.8%

Quality

EOLS — P/E HistoricalDrug Manufacturers - Specialty & Generic

Evolus, Inc. Common Stock

Sector: Healthcare

Industry: Drug Manufacturers - Specialty & Generic

Employees: 353

Evolus, Inc., a performance beauty company, delivers products in the cash-pay aesthetic market in the United States, Canada, Europe, and Australia. It offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults; and Evolysse, a collection of injectable hyaluronic acid gels, which includes various products, such as mid face, nasolabial folds, lips and eyes. The company was incorporated in 2012 and is headquartered in Newport Beach, California.

EOLS

Latest News

—

Caricamento notizie per EOLS…

stock quote shares EOLS – Evolus, Inc. Stock Price stock today

news today EOLS – Evolus, Inc. stock forecast ,stock prediction 2023 2024 2025

marketwatch EOLS – Evolus, Inc. yahoo finance google finance

stock history EOLS – Evolus, Inc. invest stock market

stock prices EOLS premarket after hours

ticker EOLS fair value insiders trading

Float Short %

Margin Of Safety %

Put/Call OI Ratio

EPS Next Q Diff

EPS Last/This Y

EPS This/Next Y

Price

Target Price

Analyst Recom

Performance Q

Upside

Beta

Ticker: EOLS

Last Quarter Act. EPS​

Avg. EPS Est. Current Quarter

Avg. EPS Est. Next Quarter

Insider Transactions

Institutional Transactions

Beta

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

Max Drawdown 5-Year %

Target Price

P/E

Forward P/E

PEG

P/S

P/B

P/Free Cash Flow

EPS

Average EPS Est. Cur. Y​

EPS Next Y. (Est.)

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

Relative Volume

Return on Equity vs Sector %

Return on Equity vs Industry %

EPS 1 7Days Diff

EPS 1 30Days Diff

EBIT Estimation

Latest News

Last Quarter Act. EPS

Average EPS Est. Cur. Y